| Venerate Home Health Express, L L C | |
| 2921 Nw 156th Street, Edmond, Oklahoma 73013 | |
| (405) 513-7794 | |
| Not Available |
| Name | Venerate Home Health Express, L L C |
|---|---|
| Location | 2921 Nw 156th Street, Edmond, Oklahoma |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 377725 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 73013, 73036, 73099, 73105, 73109, 73112, 73114, 73117, 73119, 73120, 73129, 73160 |
| Quality Rating: | Not Available* |
| * The number of patient episodes for this measure is too small to report. | |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
A pilot study conducted by a team of LSU Health New Orleans School of Medicine faculty has found that Snapchat is an effective tool to teach residents emergency radiology.
Pfizer Inc and Medivation, Inc. today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).
A five day old baby born with a heart defect has been fitted with a pacemaker at the Royal Hospital for Children in Bristol, UK and is now recovering at home.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone, in patients with castration-resistant prostate cancer (CRPC) will be highlighted in a poster presentation titled, "Phase I clinical trial of galeterone, a multifunctional anti-androgen and CYP17 inhibitor in castration resistant prostate cancer," abstract number 4665, on Sunday, June 3, 2012, 8:00 a.m. to 12:00 p.m. at the 2012 Annual Meeting of the American Society of Clinical Oncology.
› Verified 1 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | Not Available |
| Health team communicated well with them | Not Available |
| Health team discussed medicines, pain, and home safety | Not Available |
| How patients rated overall care from agency | Not Available |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
A pilot study conducted by a team of LSU Health New Orleans School of Medicine faculty has found that Snapchat is an effective tool to teach residents emergency radiology.
Pfizer Inc and Medivation, Inc. today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).
A five day old baby born with a heart defect has been fitted with a pacemaker at the Royal Hospital for Children in Bristol, UK and is now recovering at home.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone, in patients with castration-resistant prostate cancer (CRPC) will be highlighted in a poster presentation titled, "Phase I clinical trial of galeterone, a multifunctional anti-androgen and CYP17 inhibitor in castration resistant prostate cancer," abstract number 4665, on Sunday, June 3, 2012, 8:00 a.m. to 12:00 p.m. at the 2012 Annual Meeting of the American Society of Clinical Oncology.
› Verified 1 days ago
The patient survey data of Venerate Home Health Express, L L C is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 83 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 86 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 76 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 85 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 35 | 78 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
A pilot study conducted by a team of LSU Health New Orleans School of Medicine faculty has found that Snapchat is an effective tool to teach residents emergency radiology.
Pfizer Inc and Medivation, Inc. today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD).
A five day old baby born with a heart defect has been fitted with a pacemaker at the Royal Hospital for Children in Bristol, UK and is now recovering at home.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone, in patients with castration-resistant prostate cancer (CRPC) will be highlighted in a poster presentation titled, "Phase I clinical trial of galeterone, a multifunctional anti-androgen and CYP17 inhibitor in castration resistant prostate cancer," abstract number 4665, on Sunday, June 3, 2012, 8:00 a.m. to 12:00 p.m. at the 2012 Annual Meeting of the American Society of Clinical Oncology.
› Verified 1 days ago
Accentra Home Health - Central Location: 2028 E Memorial Rd, Edmond, Oklahoma 73013 Ratings: Phone: (405) 840-7775 | |
All Faith Homecare Location: 3500 South Blvd Bldg A, Suite 2, Edmond, Oklahoma 73013 Ratings: Phone: (405) 340-5100 | |
Family Care Home Health, Inc Location: 865 East 33rd, Edmond, Oklahoma 73013 Ratings: Phone: (405) 842-5656 | |
Healthback Home Health Of O K C Location: 16201 N May Ave, Edmond, Oklahoma 73013 Ratings: Phone: (405) 842-1700 | |
Lifespring Edmond Home Health Location: 424 East 2nd Street, Edmond, Oklahoma 73034 Ratings: Phone: (405) 735-6122 | |
Venerate Home Health Express, L L C Location: 2921 Nw 156th Street, Edmond, Oklahoma 73013 Ratings: NA Phone: (405) 513-7794 |